Cantabio Pharmaceuticals Status
The company acquired Lion Consulting through a reverse merger for $38.8 million, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol CTBO on December 17, 2015.
Developer of biotechnological therapies and intellectual property. The company focuses on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson?s disease, Alzheimer?s disease and other related neurodegenerative diseases. Its strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
Pre-Clinical Trials
Publicly Held
Corporation
Cantabio receives grant from Michael J. Fox Foundation to develop new detection technologies for DJ-1 protein to create a novel much needed biomarker for the potential early diagnosis and tracking of the progression of #Parkinsons disease. https://t.co/EUvLhnqJhZ
Recent publication in Annals of Neurology report #Parkinsons patient with previously unknown homozygous mutation in DJ-1 protein highlighting its importance in the on-set of #Parkinsons. https://t.co/2zhKmrzpfQ
FDA approves Tauvid™, the first novel PET imaging agent for the detection of tau protein tangles, an important pathological marker of tauopathies such as #Alzheimers and #Parkinsons, for aiding the diagnosis and progression of #Alzheimers. https://t.co/deGazaygl5 https://t.co/WIz2VnIGof
The company acquired Lion Consulting through a reverse merger for $38.8 million, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol CTBO on December 17, 2015.
Cantabio receives grant from Michael J. Fox Foundation to develop new detection technologies for DJ-1 protein to create a novel much needed biomarker for the potential early diagnosis and tracking of the progression of #Parkinsons disease. https://t.co/EUvLhnqJhZ
Recent publication in Annals of Neurology report #Parkinsons patient with previously unknown homozygous mutation in DJ-1 protein highlighting its importance in the on-set of #Parkinsons. https://t.co/2zhKmrzpfQ
FDA approves Tauvid™, the first novel PET imaging agent for the detection of tau protein tangles, an important pathological marker of tauopathies such as #Alzheimers and #Parkinsons, for aiding the diagnosis and progression of #Alzheimers. https://t.co/deGazaygl5 https://t.co/WIz2VnIGof
https://t.co/f1MH0rTAmo A special day on April 11th, World Parkinson’s Day, Let's keep going until we find a cure!
An advice from @MichaelJFoxOrg on COVID-19 for #Parkinson’s patients. https://t.co/HUok2zYnVO
There is always challenge to fill up clinical trials for #Parkinsons. 85 percent of trials face delays and 30 percent never get off the ground because of a lack of volunteers, resulting in a dramatic slowdown in progress toward a cure. Please check out @MichaelJFoxOrg now! https://t.co/8jqPEb7ttl
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review